Wednesday, December 1, 2021

Startup Redmond found that Johnson & Johnson’s breakout cases had higher hospital admissions rates compared to other COVID vaccines.

A study of nearly 2 million people vaccinated against the coronavirus found that those who received the Moderna and Pfizer vaccines were less likely to be hospitalized after a breakthrough infection than people who received the Johnson & Johnson vaccine.

Truveta, a Redmond-based startup that pooled data from 20 US health care systems from 42 states, released new results on Tuesday morning. They are based on an analysis of 1.7 million vaccinated people living in the United States. The company hopes its dataset, which is updated daily, will provide a more comprehensive view of the health of Americans in general.

“If we’re going to study our country, we need data from our country,” said Terry Myerson, CEO of Truveta, noting that the FDA has so far relied heavily on research from in Israel to issue a booster vaccine manual. shots.

The company found that 9% of Pfizer and Moderna vaccinated patients with breakthrough infections end up hospitalized. In contrast, the same rate is 15% for those who received the J&J vaccine. Pfizer and Moderna vaccines are based on a technology called mRNA, while J&J vaccines use another traditional technology called adenovirus.

Truveta also found that people with high-risk illnesses such as cancer, organ transplants, or HIV are twice as likely to be hospitalized if they have a breakthrough infection.

Of all the high-risk conditions studied, the company found that people with chronic kidney disease were hospitalized with breakthrough infections with the highest frequency, at 25%.

Read Also:  Canadian fishing camp owner awaits border opening on Monday

The study also found that less than 1% of fully vaccinated people experience side effects from the vaccines, but people vaccinated with the Moderna vaccine showed 40% more side effects than Pfizer.

Truveta’s database includes about 35 million people, accounting for 16% of clinical care in the United States. However, the first study the company conducted was based on a subset of these people, a total of 1.7 million people, based on data that it “de-identified” or verified for privacy and security, and which they knew was “high probability ”were fully vaccinated.

Access to the platform will be sold to large healthcare systems and life sciences companies across the country. Right now, it is only being used by the “pioneers”.

Ultimately, Myerson said the company will seek to work with the government to leverage the impact of its dataset. When asked if the company plans to charge the government for accessing the data, or if it will freely share it with agencies, the company replied, “We welcome talking with the government to explore options.”

The company has raised nearly $ 200 million to date, mostly from large healthcare systems that have pledged to share their data with the platform. Microsoft, where Myerson previously ran Windows, also invested in the company. The amount was not disclosed. The company uses Microsoft Azure cloud technology to host most of its platform.

This story will be updated.

More on the COVID-19 pandemic

Nation World News Deskhttps://nationworldnews.com
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news
- Advertisement -